Ejtahed H-S, Soroush A-R, Angoorani P, Larijani B, Hasani-Ranjbar S. Gut microbiota as a target in the pathogenesis of metabolic disorders: a new approach to novel therapeutic agents. Horm Metab Res. 2016;48(06):349–58.

Article  CAS  PubMed  Google Scholar 

Gregg EW, Shaw JE. Global health effects of overweight and obesity. N Engl J Med. 2017;377(1):80–1.

Article  PubMed  Google Scholar 

Lobstein T, Jackson-Leach R, Powis J. Obesity Atlas 2023. World Obesity Federation; London, UK; 2023.

Dattani S, Spooner F, Ritchie H, Roser M. Causes of death. Our World in Data; 2023. https://ourworldindata.org/grapher/annual-number-of-deaths-by-cause

Jafari-Adli S, Jouyandeh Z, Qorbani M, Soroush A, Larijani B, Hasani-Ranjbar S. Prevalence of obesity and overweight in adults and children in Iran; a systematic review. J Diabetes Metab Disord. 2014;13:1–10.

Article  Google Scholar 

Vardell E. Global health observatory data repository. Med Ref Serv Q. 2020;39(1):67–74.

Article  PubMed  Google Scholar 

Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science. 2005;307(5717):1909–14.

Article  CAS  PubMed  Google Scholar 

Seo S, Ju S, Chung H, Lee D, Park S. Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats. Endocr J. 2008;55(5):867–74.

Article  CAS  PubMed  Google Scholar 

Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Investig. 2014;124(10):4473–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mechanick JI, Harrell R, Allende-Vigo MZ, Alvayero C, Arita-Melzer O, Aschner P, et al. Transculturalization recommendations for developing latin American clinical practice algorithms in endocrinology proceedings of the 2015 pan-american workshop by the American association of clinical endocrinologists and American college of endocrinology. Endocr Pract. 2016;22(4):476–501.

Article  PubMed  Google Scholar 

Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American association of clinical endocrinologists and American College of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22:1–203.

Article  PubMed  Google Scholar 

Daneschvar HL, Aronson MD, Smetana GW. FDA-approved anti-obesity drugs in the United States. Am J Med. 2016;129(8):879.e1–e6.

Article  CAS  PubMed  Google Scholar 

Thomas EA, Mcnair B, Bechtell JL, Ferland A, Cornier MA, Eckel RH. Greater hunger and less restraint predict weight loss success with phentermine treatment. Obesity. 2016;24(1):37–43.

Article  CAS  PubMed  Google Scholar 

Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

16. Diabetes Care in the hospital: standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Supplement1):S295–306.

Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabol. 2018;27(4):740–56.

Article  CAS  Google Scholar 

Martin CK, Redman LM, Zhang J, Sanchez M, Anderson CM, Smith SR, et al. Lorcaserin, a 5-HT2C receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metabolism. 2011;96(3):837–45.

Article  CAS  Google Scholar 

https://www.fda.gov/drugs/drug-safety-and-availability/safety-clinical-trial-shows-possible-increased-risk-cancerweight-loss-medicine-belviq-belviq-xr.

Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532–46.

Article  CAS  PubMed  Google Scholar 

Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, et al. The science of obesity management: an endocrine society scientific statement. Endocr Rev. 2018;39(2):79–132.

Article  PubMed  PubMed Central  Google Scholar 

Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52.

Article  CAS  PubMed  Google Scholar 

Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906–13.

Article  CAS  PubMed  Google Scholar 

Axel AMD, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of α1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology. 2010;35(7):1464–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hansen HH, Jensen MM, Overgaard A, Weikop P, Mikkelsen JD. Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat. Pharmacol Biochem Behav. 2013;110:265–71.

Article  CAS  PubMed  Google Scholar 

Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Under-reporting of adverse effects of tesofensine. Lancet. 2013;382(9887):127.

Article  PubMed  Google Scholar 

Halpern B, Mancini MC. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. Exp Opin Drug Saf. 2017;16(1):27–39.

Article  CAS  Google Scholar 

Cowley MA, Smart JL, Rubinstein M, Cerdán MG, Diano S, Horvath TL, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature. 2001;411(6836):480–4.

Article  CAS  PubMed  Google Scholar 

Kelly MJ, Loose MD, Ronnekleiv OK. Opioids hyperpolarize β-endorphin neurons via µ-receptor activation of a potassium conductance. Neuroendocrinology. 1990;52(3):268–75.

Article  CAS  PubMed  Google Scholar 

Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1–11.

Article  CAS  PubMed  Google Scholar 

Greenway FL, Whitehouse M, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, et al. Rational design of a combination medication for the treatment of obesity. Obesity. 2009;17(1):30–9.

Article  CAS  PubMed  Google Scholar 

Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605.

Article  CAS  PubMed  Google Scholar 

Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR‐II). Obesity. 2013;21(5):935–43.

Article  CAS  PubMed  Google Scholar 

Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O’neil PM, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011;19(1):110–20.

Article  CAS  PubMed  Google Scholar 

Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–9.

Article  CAS  PubMed  PubMed Central